{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000049","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.162606+00:00","generated_at":"2026-06-03T00:31:55.259763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive","bullets":["Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.","Restructuring completed with $50-55M annual cost savings; headcount reduced ~25%.","Company expects to be cash flow positive (ex buybacks) in Q2 2024, ahead of prior guidance.","Reaffirms FY2024 net product revenue guidance of $200-220M.","FDA approved label update for LUPKYNIS removing one-year efficacy limitation; quarterly kidney assessment after year one."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000049","json":"https://secwatch.observer/filing/0001600620-24-000049.json","markdown":"https://secwatch.observer/filing/0001600620-24-000049.md","text":"https://secwatch.observer/filing/0001600620-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/0001600620-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/auph-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:31:55.259763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9a07e6ce7a1110bdcfa90a5b0f6cdde13e9ee0f","claim":"Aurinia Pharmaceuticals Inc. reported the quarter ended March 31, 2024 results: revenue $50.3 million. Guidance reaffirmed.","evidence_excerpt":"set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS • Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/0001600620-24-000049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$50.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}